Dispatch Bio launches with $216M to target solid tumors

Dispatch Bio announced its official launch, having raised a total of $216 million to engineer a universal CAR-T treatment across solid tumors.

The Series A syndicate includes founding investors ARCH Venture Partners and Parker Institute for Cancer Immunotherapy along with Bristol Myers Squibb, the University of Pennsylvania, Stanford University, and Alexandria Venture Investments.

Proceeds from the financing will be used to advance Dispatch’s therapeutic candidates into first-in-human clinical studies and beyond, with the first program expected to enter the clinic in 2026.

Dispatch’s proprietary Flare platform is engineered to overcome the challenges of treating solid tumors: the lack of a tumor-specific target and the presence of an immune-suppressive tumor microenvironment. The platform works by delivering a viral vector carrying a novel, universal antigen – called Flare – that precisely tags solid tumor cells while simultaneously breaking down the tumor’s inhibitory environment. Once in place, the Flare antigen acts as a beacon, directing CAR-T cells to target and clear the cancer cells — without harming healthy tissue.

Dispatch was established through a collaboration with the Parker Institute for Cancer Immunotherapy and relies on technologies from the laboratories of Andy Minn, MD, Ph.D.; Carl June, MD; Chris Garcia, Ph.D.; and Kole Roybal, Ph.D.